Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Archives of Psychiatry and Clinical Neuroscience
Published in: European Archives of Psychiatry and Clinical Neuroscience 2/2010

01-11-2010 | Original Article

Therapy-refractory panic: current research areas as possible perspectives in the treatment of anxiety

Authors: J. Diemer, N. Vennewald, K. Domschke, P. Zwanzger

Published in: European Archives of Psychiatry and Clinical Neuroscience | Special Issue 2/2010

Login to get access

Abstract

Panic disorder (PD) is characterized by recurrent panic attacks that are defined as distinct episodes of intense fear, accompanied by symptoms related to physical arousal. Because most patients interpret these symptoms as signs of serious somatic disease (e.g., a heart attack), utilization of healthcare services is high in PD sufferers. PD can become debilitating, interfering significantly with patients’ lives. Fortunately, effective treatments are available, but a considerable proportion of patients do not respond sufficiently. The aim of this paper is to outline some promising research strategies aimed at improving established treatments.
Literature
1.
Kessler RC, Chiu WT, Jin R et al (2006) The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry 63:415–424CrossRefPubMed
2.
Bandelow B (2003) Epidemiology of depression and anxiety. In: Kasper S (ed) Handbook on depression and anxiety. M. Dekker, New York, pp 49–68
3.
Barlow DH (2002) Anxiety and its disorders: the nature and treatment of anxiety and panic. Guilford Press, New York
4.
Katon W (1996) Panic disorder: relationship to high medical utilization, unexplained physical symptoms, and medical costs. J Clin Psychiatry 57:11–22PubMed
5.
Baldwin DS, Anderson IM, Nutt DJ et al (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 9:567–596CrossRef
6.
Bandelow B, Zohar J, Hollander E et al (2008) World federation of societies of biological psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders—first revision. World J Biol Psychiatry 9:248–312
7.
Cloos JM (2005) The treatment of panic disorder. Curr Opin Psychiatry 18:45–50PubMed
8.
Mattick RP, Andrews G, Hadzi-Pavlovic D et al (1990) Treatment of panic and agoraphobia: an integrative review. J Nerv Ment Dis 178:567–576CrossRefPubMed
9.
Gould RA, Otto MO, Pollack MH (1995) A meta-analysis of treatment outcome for panic disorder. Clin Psychol Rev 15:819–844CrossRef
10.
Ballenger JC (1998) Treatment of panic disorder in the general medical setting. J Psychosom Res 44:5–15CrossRefPubMed
11.
Bandelow B, Rüther E (2004) Treatment-resistant panic disorder. CNS Spectr 9:725–739PubMed
12.
McIntosh A, Cohen A, Turnbull N et al (2004) Clinical guidelines and evidence review for panic disorder and generalised anxiety disorder. National Collaborating Centre for Primary Care, Sheffield
13.
Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Panic Disorder and Agoraphobia (2003) Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Aust and N Z J Psychiatry 37:641–656
14.
AKDÄ (2003) Therapieempfehlungen der Arzneimittelkommission der deutschen Ärzteschaft. Empfehlungen zur Therapie von Angst- und Zwangsstörungen
15.
Zwanzger P, Diemer J, Jabs B (2008) Comparison of combined psycho-and pharmacotherapy with monotherapy in anxiety disorders: controversial viewpoints and clinical perspectives. J Neural Transm 116:759–765CrossRefPubMed
16.
17.
Bandelow B, Seidler-Brandler U, Becker A et al (2007) Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry 8:175–187CrossRefPubMed
18.
Kapfhammer HP (2008) Psychotherapy and pharmacotherapy of anxiety disorders. Neuropsychiatry 22:51–70
19.
Schneider S, Margraf J (1998) Agoraphobie und Panikstörung. Hogrefe, Göttingen
20.
21.
Ehlers A, Margraf J (1989) Psychophysiological model of panic attacks. Swets & Zeitlinger, Amsterdam
22.
Gloster AT, Wittchen HU, Einsle F et al (2009) Mechanism of action in CBT (MAC): methods of a multi-center randomized controlled trial in 369 patients with panic disorder and agoraphobia. Eur Arch Psychiatry Clin Neurosci 259:155–166CrossRef
23.
Arolt V, Zwanzger P, Ströhle A et al (2009) Das Forschungsnetzwerk PANIC-NET—Von einem besseren Verständnis neurobiologischer Mechanismen der Furchtregulation zu effektiverer psychotherapeutischer Behandlung in der Praxis. Psychother Psych Med 59:124–131CrossRef
24.
Botella B, García-Palacios A, Villa H et al (2007) Virtual reality exposure in the treatment of panic disorder and agoraphobia: a controlled study. Clin Psychol Psychother 14:164–175CrossRef
25.
Gregg L, Tarrier N (2007) Virtual reality in mental health: a review of the literature. Soc Psychiatry Psychiatr Epidemiol 42:343–354CrossRefPubMed
26.
27.
Emmelkamp PMG, Krijn M, Hulsbosch AM et al (2002) Virtual reality treatment versus exposure in vivo: a comparative evaluation in acrophobia. Behav Res Ther 40:509–516CrossRefPubMed
28.
Mühlberger A, Weik A, Pauli P et al (2006) One-session virtual reality exposure treatment for fear of flying: 1-year follow-up and graduation flight accompaniment effects. Psychother Res 16:26–40CrossRef
29.
Rothbaum BO, Hodges L, Anderson PL et al (2002) Twelve-month follow-up of virtual reality and standard exposure therapies for the fear of flying. J Consult Clin Psychol 70:428–432CrossRefPubMed
30.
Starcevic V (2008) Treatment of panic disorder: recent developments and current status. Expert Rev Neurother 8:1219–1232CrossRefPubMed
31.
Ressler KJ, Rothbaum BO, Tannenbaum L et al (2004) Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 1:1136–1144CrossRef
32.
Otto MW, Tolin DF, Simon NM et al (2009) Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry 67:365–370CrossRefPubMed
33.
Barker AT, Jalinous R, Freeston IL (1985) Non-invasive magnetic stimulation of human motor cortex. Lancet 1:1106–1107CrossRefPubMed
34.
LeDoux JE, Cicchetti P, Xagoraris A et al (1990) The lateral amygdaloid nucleus: sensory interface of the amygdala in fear conditioning. J Neurosci 10:1062–1069PubMed
35.
36.
Gorman JM, Kent JM, Sullivan GM et al (2000) Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 157:493–505CrossRefPubMed
37.
38.
Hariri AR, Bookheimer SY, Mazziotta JC (2000) Modulating emotional responses: effects of a neocortical network on the limbic system. Neuroreport 11:43–48CrossRefPubMed
39.
Hariri AR, Mattay VS, Tessitore A et al (2003) Neocortical modulation of the amygdala response to fearful stimuli. Biol Psychiatry 53:494–501CrossRefPubMed
40.
Taylor SF, Phan KL, Decker LR et al (2003) Subjective rating of emotionally salient stimuli modulates neural activity. Neuroimage 18:650–659CrossRefPubMed
41.
Davidson RJ, Abercrombie H, Nutt DJ et al (1999) Regional brain function, emotion and disorders of emotion. Curr Opin Neurobiol 9:228–234CrossRefPubMed
42.
Heller W, Nitschke JB (1998) The puzzle of regional brain activity in depression and anxiety: the importance of subtypes and comorbidity. Cogn Emot 12:421–447CrossRef
43.
Van Honk J, Tuiten A, Van Den Hout M et al (1998) Baseline salivary cortisol levels and preconscious selective attention for threat: a pilot study. Psychoneuroendocrinology 23:741–747CrossRefPubMed
44.
Van Honk J, Tuiten A, Verbaten R et al (1999) Correlations among salivary testosterone, mood, and selective attention to threat in humans. Horm Behav 36:17–24CrossRefPubMed
45.
Zwanzger P, Fallgatter AJ, Zavorotnyy M et al (2009) Anxiolytic effects of transcranial magnetic stimulation—an alternative treatment option in anxiety disorders? J Neural Transm 116:767–775CrossRefPubMed
46.
Garcia-Toro M, Salva CJ, Crespi FM et al (2002) Panic disorder and transcranial magnetic stimulation. Actas Esp Psiquiatr 30:221–224PubMed
47.
Mantovani A, Lisanby SH, Pieraccini F et al (2007) Repetitive transcranial magnetic stimulation (rTMS) in the treatment of panic disorder (PD) with comorbid major depression. J Affect Disord 102:277–280CrossRefPubMed
48.
Zwanzger P, Minov C, Ella R et al (2002) Transcranial magnetic stimulation for panic. Am J Psychiatry 159:315–316CrossRefPubMed
49.
Zwanzger P, Eser D, Volkel N et al (2007) Effects of repetitive transcranial magnetic stimulation (rTMS) on panic attacks induced by cholecystokinin-tetrapeptide (CCK-4). Int J Neuropsychopharmacol 10:285–289CrossRefPubMed
50.
Prasko J, Zalesky R, Bares M et al (2007) The effect of repetitive transcranial magnetic stimulation (rTMS) add on serotonin reuptake inhibitors in patients with panic disorder: a randomized, double blind sham controlled study. Neuro Endocrinol Lett 28:33–38PubMed
51.
52.
DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW (eds) (2009) für die Leitliniengruppe Unipolare Depression. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression-Kurzfassung, 1. Auflage 2009. DGPPN, ÄZQ, AWMF—Berlin, Düsseldorf
53.
Barlow DH, Gorman JM, Shear MK et al (2000) Cognitive-behavioral therapy, imipramine or their combination for panic disorder: a randomized controlled trial. J Am Med Assoc 283:2529–2536CrossRef
54.
van Apeldoorn FJ, Timmerman ME, Mersch PP et al (2010) A randomized trial of cognitive-behavioral therapy or selective serotonin reuptake inhibitor or both combined for panic disorder with or without agoraphobia: treatment results through 1-year follow-up. J Clin Psychiatry 71:574–586CrossRefPubMed
Metadata
Title
Therapy-refractory panic: current research areas as possible perspectives in the treatment of anxiety
Authors
J. Diemer
N. Vennewald
K. Domschke
P. Zwanzger
Publication date
01-11-2010
Publisher
Springer-Verlag
Published in
European Archives of Psychiatry and Clinical Neuroscience / Issue Special Issue 2/2010
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-010-0143-9

Other articles of this Special Issue 2/2010

European Archives of Psychiatry and Clinical Neuroscience 2/2010 Go to the issue

Review

Intervention in at-risk states for developing psychosis

Editorial

Psychiatric illness through the lifespan

Review

Individualised treatment in alcohol-dependent patients

Review

Is there a personalized medicine for mood disorders?

Review

Ethics in psychiatry: the lessons we learn from Nazi psychiatry

Original Paper

Differential expression of presynaptic genes in a rat model of postnatal hypoxia: relevance to schizophrenia